Literature DB >> 27890288

Ferret Oncology: Diseases, Diagnostics, and Therapeutics.

Nico J Schoemaker1.   

Abstract

Neoplastic disease is common in ferrets. Approximately half of all tumors diagnosed in ferrets are located in the endocrine or hemolymphatic system. Many factors may influence the choice of treatment. Medical management of adrenal tumors has a greater disease-free period compared to adrenalectomy. In ferrets with an insulinoma, no difference is seen in the mean survival time of medically and surgically treated patients. Aside from medical and surgical treatment modalities, chemotherapy and radiation therapy have also been described in ferrets in other types of tumors. The outcome of these treatment modalities is not always favorable. Copyright Â
© 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Hyperadrenocorticism; Insulinoma; Lymphoma; Mustela putorius furo; Neoplasia; Neoplasm

Mesh:

Year:  2017        PMID: 27890288     DOI: 10.1016/j.cvex.2016.07.004

Source DB:  PubMed          Journal:  Vet Clin North Am Exot Anim Pract        ISSN: 1094-9194


  4 in total

1.  Lifetime cancer prevalence and life history traits in mammals.

Authors:  Amy M Boddy; Lisa M Abegglen; Allan P Pessier; Athena Aktipis; Joshua D Schiffman; Carlo C Maley; Carmel Witte
Journal:  Evol Med Public Health       Date:  2020-05-25

2.  Characterisation of the French ferret population, husbandry, reported medical care and feeding habits.

Authors:  Géraldine Blanchard; Maud Marsot; Roselyne Bourassin; Bernard-Marie Paragon; Jean-Jacques Benet; Adeline Linsart
Journal:  J Nutr Sci       Date:  2018-01-31

3.  Electrochemotherapy with Bleomycin of Different types of Cutaneous Tumours in a Ferret (Mustela Putorius Furo).

Authors:  Jozko Racnik; Tanja Svara; Marko Zadravec; Mitja Gombac; Maja Cemazar; Gregor Sersa; Natasa Tozon
Journal:  Radiol Oncol       Date:  2017-12-07       Impact factor: 2.991

Review 4.  The Role of Bcl-xL Protein Research in Veterinary Oncology.

Authors:  Aleksandra Pawlak; Marta Henklewska
Journal:  Int J Mol Sci       Date:  2020-04-04       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.